Title : Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.

Pub. Date : 2001 Aug

PMID : 11558859






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The 5- and 10-mg doses of ezetimibe significantly reduced LDL-C levels by 15.7% and 18.5%, respectively (P < 0.01 vs placebo) and significantly increased high-density lipoprotein cholesterol (hDL-C) levels by 2.9% and 3.5%, respectively (P < 0.05 vs placebo). Ezetimibe component of oligomeric golgi complex 2 Homo sapiens
2 With the 10-mg dose of ezetimibe, 67.8% of patients achieved > or = 15% reduction in plasma LDL-C levels, and 22.0% achieved > or = 25% reduction. Ezetimibe component of oligomeric golgi complex 2 Homo sapiens
3 The decrease in plasma LDL-C levels was significantly greater with ezetimibe 10 mg compared with ezetimibe 5 mg (P < 0.05). Ezetimibe component of oligomeric golgi complex 2 Homo sapiens
4 The decrease in plasma LDL-C levels was significantly greater with ezetimibe 10 mg compared with ezetimibe 5 mg (P < 0.05). Ezetimibe component of oligomeric golgi complex 2 Homo sapiens